Urticaria is a common disorder which affects up to 20% of population. It can present with or without angioedema. The most common causes of angioedema are angiotensin-converting enzyme (ACE) inhibitor-induced angioedema and idiopathic angioedema. Hereditary angioedema (HAE) or acquired angioedema (AAE) are much rarer. The management of urticaria and angioedema involves both prophylaxis to prevent the episodes of attack and pharmacotherapy to treat the attacks. The first line therapies for bradykinin-mediated angioedema are C1 inhibitor, Ecallantide, Icatibant, otherwise, the older therapies such as plasma, attenuated androgens can also be useful. Second generation of antihistamines are always the mainstay therapy for acute and chronic urticaria. Steroids and Omalizumab can be added to the antihistamine strategies to enhance the performance. This thesis mainly focuses on causes, diagnosis and management of urticaria (with or without angioedema) and also the newer therapy that has been proved by FDA.